Journal Article

Impact of the pretreatment prognostic nutritional index on the survival after first‐line immunotherapy in non‐small‐cell lung cancer patients

Okamoto, Isamu, Yoshizumi, Tomoharu, Haratake, Naoki, Shimokawa, Mototsugu, Oku, Yuka, Takeoka, Hiroaki, Wakasu, Sho, Shoji, Fumihiro, Shiraishi, Yoshimasa, Kosai, Keisuke, Fujimoto, Airi, Takeo, Sadanori, Nakashima, Naoki, Kinoshita, Fumihiko, Takada, Kazuki, Takenaka, Tomoyoshi, Tanaka, Kentaro, Takamori, Shinkichi, Yamashita, Takanori, Nagano, Taichi, Seto, Takashi, Okamoto, Masaki, Okamoto, Tatsuro, Toyokawa, Gouji, Yamazaki, Koji, Ueda, Hitoshi, Watanabe, Kenji, Higashijima, Kodo

2023

Overview

Background Immunotherapy has become a standard‐of‐care for patients with non‐small‐cell lung cancer (NSCLC). Although several biomarkers, such as programmed cell death‐1, have been shown to be useful in selecting patients likely to benefit from immune checkpoint inhibitors (ICIs), more useful and reliable ones should be investigated. The prognostic nutritional index (PNI) is a marker of the immune and nutritional status of the host, and is derived from serum albumin level and peripheral lymphocyte count. Although several groups reported its prognostic role in patients with NSCLC receiving a single ICI, there exist no reports which have demonstrated its role in the first‐line ICI combined with or without chemotherapy. Materials and Methods Two‐hundred and eighteen patients with NSCLC were included in the current study and received pembrolizumab alone or chemoimmunotherapy as the first‐line therapy. Cutoff value of the pretreatment PNI was set as 42.17. Results Among 218 patients, 123 (56.4%) had a high PNI (≥42.17), while 95 (43.6%) had a low PNI (<42.17). A significant association was observed between the PNI and both the progression‐free survival (PFS; hazard ratio [HR] =  0.67, 95% confidence interval [CI]: 0.51–0.88, p =  0.0021) and overall survival (OS; HR = 0.46, 95% CI: 0.32–0.67, p < 0.0001) in the entire population, respectively. The multivariate analysis identified the pretreatment PNI as an independent prognosticator for the PFS (p =  0.0011) and OS (p  < 0.0001), and in patients receiving either pembrolizumab alone or chemoimmunotherapy, the pretreatment PNI remained an independent prognostic factor for the OS (p = 0.0270 and 0.0006, respectively). Conclusion The PNI might help clinicians appropriately identifying patients with better treatment outcomes when receiving first‐line ICI therapy.

• Publisher: John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
• Subject: Apoptosis / Biomarkers / Body mass index / Cancer therapies / Cell death / Cell number / chemoimmunotherapy / Chemotherapy / first‐line immunotherapy / Histology / Hospitals / Immune checkpoint inhibitors / Immunotherapy / Ligands / Lung cancer / Lymphocytes / Medical prognosis / Medical records / Missing data / Monoclonal antibodies / monotherapy / Multivariate analysis / Non-small cell lung carcinoma / non‐small‐cell lung cancer / Nutritional status / Patients / Pembrolizumab / prognostic nutritional index / Response rates / Small cell lung carcinoma / Tomography